"Both companies are passionate about developing new cancer therapies for patients and are excited about the potential of immunotherapies. We are pleased to be joining AstraZeneca/MedImmune, who will work with us to further advance the pioneering research we’ve been conducting in this area"
Michael Richman, President and Chief Executive Officer, AmplimmuneRead case study (PDF 558kb)
“Joining AstraZeneca has enabled us to create a unique operating model. We have retained the culture and adaptive development approach that has allowed Ardea to so rapidly progress our candidate molecules for the treatment of gout, hyperuricemia and other inflammatory
James Mackay, President and Chief Operating Officer, Ardea BiosciencesRead case study (PDF 397kb)
AstraZeneca, with its biologics arm MedImmune, entered into a global collaboration with Amgen in April 2012 to co-develop and commercialize five monoclonal antibodies from Amgen’s clinical portfolio across a range of inflammatory indications. The number of molecules and indications involved make it one of the biggest peer-to-peer deals ever completed within the industry and sets a benchmark for other companies pursuing similar deal structures.Read case study (PDF 408kb)
Hutchison Medi Pharma
We entered into a global licensing, co-development, and commercialisation agreement for Volitinib (HMPL-504) with Hutchison Medi Pharma in December 2011.Read case study (PDF 256kb)